The UK's ReNeuron Group says a paper has been published in the journal Biotechnology Letters, demonstrating successful automation of the manufacturing if its ReN001 neural stem cell line for stroke.
The research was conducted in collaboration with the remedi Project at Loughborough University, UK. ReNeuron's standard cell manufacturing process was adapted and transferred to an automated system using a commercially-available robotic cell culture system - the CompacT SelecT designed and manufactured by The Automation Partnership, an innovative UK-based company focused on the development of advanced automated systems for the global life sciences market. With minor modifications of the standard process, the robot was programmed to successfully manufacture a batch of cells. The growth rate and the quality characteristics were identical to those produced manually.
John Sinden, chief scientific officer of ReNeuron, said: "the successful automation of our ReN001 manufacturing process heralds two exciting advances. Firstly, ReNeuron has access to a precise platform allowing optimization of its cell culture process, leading to lower costs and increased yield. Secondly, we anticipate that automation will deliver a more reliable scale of manufacture progressing the therapy into later stage trials and beyond."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze